OS and progression in published studies including NMZL patients
| Study . | No. of patients . | 5-y OS rate, % . | Median OS, y . | Median progression, y . |
|---|---|---|---|---|
| Armitage et al (1998)15 | 25 | 57 | ND | ND |
| Nathwani et al (1999)44 | 20 | 56 | ND | ND |
| Berger et al (2000)11 | 37 | 55 | ND | ND |
| Camacho et al (2003)16 | 22 | 79 | ND | ND |
| Arcaini et al (2004)13 | 9 | ND | Not reached | 2.8 |
| Traverse-Glehen et al (2006)12 | 21 | 64 | ND | 1.3 |
| Oh et al (2006)18 | 36 | 83 | 5.5 | 1.3 |
| Arcaini et al (2007)14 | 47 | 69 | Not reached | 2.6 |
| Kojima et al (2007)45 | 65 | 85 | ND | ND |
| Orciuolo (2010)46 | 89 | 96 | ND | ND |
| Heilgeist et al (2012)20 | 32 | 89 | ND | ND |
| Olszewski & Castillo (SEER) (2013)10 | 4724 | 77* | ND | ND |
| Study . | No. of patients . | 5-y OS rate, % . | Median OS, y . | Median progression, y . |
|---|---|---|---|---|
| Armitage et al (1998)15 | 25 | 57 | ND | ND |
| Nathwani et al (1999)44 | 20 | 56 | ND | ND |
| Berger et al (2000)11 | 37 | 55 | ND | ND |
| Camacho et al (2003)16 | 22 | 79 | ND | ND |
| Arcaini et al (2004)13 | 9 | ND | Not reached | 2.8 |
| Traverse-Glehen et al (2006)12 | 21 | 64 | ND | 1.3 |
| Oh et al (2006)18 | 36 | 83 | 5.5 | 1.3 |
| Arcaini et al (2007)14 | 47 | 69 | Not reached | 2.6 |
| Kojima et al (2007)45 | 65 | 85 | ND | ND |
| Orciuolo (2010)46 | 89 | 96 | ND | ND |
| Heilgeist et al (2012)20 | 32 | 89 | ND | ND |
| Olszewski & Castillo (SEER) (2013)10 | 4724 | 77* | ND | ND |
ND, not done
Relative survival.